- Home
- ARQQ vs IPHA Comparison
ARQQ vs IPHA Comparison
Compare ARQQ & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQQ
- IPHA
- Stock Information
- Founded
- ARQQ 2017
- IPHA 1999
- Country
- ARQQ United Kingdom
- IPHA France
- Employees
- ARQQ N/A
- IPHA N/A
- Industry
- ARQQ Computer Software: Prepackaged Software
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- ARQQ Technology
- IPHA Health Care
- Exchange
- ARQQ Nasdaq
- IPHA Nasdaq
- Market Cap
- ARQQ 309.4M
- IPHA 160.1M
- IPO Year
- ARQQ N/A
- IPHA 2019
- Fundamental
- Price
- ARQQ $21.56
- IPHA $2.19
- Analyst Decision
- ARQQ Strong Buy
- IPHA Strong Buy
- Analyst Count
- ARQQ 1
- IPHA 1
- Target Price
- ARQQ $52.00
- IPHA $11.00
- AVG Volume (30 Days)
- ARQQ 1.2M
- IPHA 28.8K
- Earning Date
- ARQQ 05-22-2025
- IPHA 03-27-2025
- Dividend Yield
- ARQQ N/A
- IPHA N/A
- EPS Growth
- ARQQ N/A
- IPHA N/A
- EPS
- ARQQ 0.48
- IPHA N/A
- Revenue
- ARQQ $241,000.00
- IPHA $20,831,349.00
- Revenue This Year
- ARQQ $1,818.77
- IPHA $209.83
- Revenue Next Year
- ARQQ N/A
- IPHA $83.15
- P/E Ratio
- ARQQ $44.51
- IPHA N/A
- Revenue Growth
- ARQQ N/A
- IPHA N/A
- 52 Week Low
- ARQQ $3.72
- IPHA $1.29
- 52 Week High
- ARQQ $52.79
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- ARQQ 55.23
- IPHA 54.38
- Support Level
- ARQQ $21.56
- IPHA $2.11
- Resistance Level
- ARQQ $32.90
- IPHA $2.24
- Average True Range (ATR)
- ARQQ 3.83
- IPHA 0.10
- MACD
- ARQQ 0.23
- IPHA -0.01
- Stochastic Oscillator
- ARQQ 36.36
- IPHA 42.39
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product QuantumCloud. The firm operates in one segment that is, the provision of cybersecurity services via satellite and terrestrial platforms. The company operates and generates its revenue from UK.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.